Global RNA Therapeutics Market Size Study and Forecast by Type, By Indication, By End User, and Regional Forecasts 2026-2036

Global RNA Therapeutics Market Definition & Scope

The Global RNA Therapeutics Market, valued at USD 8.50 Billion in 2025, is projected to reach USD 31.76 Billion by 2036, expanding at a CAGR of 13.67% during the forecast period. RNA therapeutics are a sophisticated class of medicines that harness ribonucleic acid (RNA) molecules to control gene expression, turn off disease-causing genes, replace faulty proteins or activate targeted immune responses. These therapies include mRNA-based therapeutics, RNA interference (RNAi), antisense oligonucleotides (ASOs) and other RNA-based modalities, offering highly targeted treatment approaches for a wide range of diseases including infectious diseases, cancer, cardiovascular disorders, neurological conditions and rare genetic diseases. The market is served to hospitals, research institutions, biopharmaceutical companies, biotechnology companies, and contract research and manufacturing organizations involved in RNA drug discovery, development, and commercialization.

The market is growing at a robust pace owing to the increasing clinical success of RNA-based medicines, increasing investments in precision medicine, increasing prevalence of chronic and genetic disorders, and ongoing advancements in RNA delivery technologies. The market is expanding due to the successful commercialization of mRNA platforms, growing research in gene silencing technologies, expanding applications of antisense therapeutics, and increasing pharmaceutical partnerships. The World Health Organization (WHO) reports that non-communicable diseases remain the leading cause of death worldwide, underscoring the significance of creating innovative targeted therapies to address previously difficult-to-treat diseases. The global RNA therapeutics market is expected to deliver significant long-term growth opportunities during the forecast period, supported by continued advancements in lipid nanoparticle (LNP) delivery systems, gene editing technologies, AI-assisted drug discovery, personalized RNA medicine, next-generation oligonucleotide chemistry, and scalable RNA manufacturing platforms.

Global RNA Therapeutics Market: Key Highlights

• Global RNA Therapeutics Market is forecasted to reach USD 8.50 Billion in 2025. Market growth is attributed to the rising clinical success of RNA-based medicines, increasing prevalence of chronic and genetic diseases, growing investments in precision medicine, and rapid technological advancements in RNA delivery technologies.
• The market is projected to reach USD 31.76 Billion by 2036, growing at a CAGR of 13.67% from 2026 to 2036. The growth is driven by the growing commercialisation of mRNA therapeutics, growing pipelines of RNA interference (RNAi), rising pharma collaborations and continuous innovation in lipid nanoparticle (LNP) delivery systems.
• North America holds the largest share in the global market of 43.6% in 2025. The region has strong biotech ecosystems, high pharmaceutical R&D expenditure, supportive regulatory environments, advanced genomic research infrastructure and the presence of leading RNA therapeutics developers.
• The Asia Pacific is expected to experience the highest CAGR of 15.2% during 2026-2036. The growth can be attributed to the rising biotechnology industries, increasing healthcare investments, growing government support for genomics research, and increasing clinical trial activity in China, Japan, South Korea, India, and Singapore.
• mRNA-based Therapeutics dominated the type segment with an estimated market share of 42.8% in 2025. This segment is expected to dominate the market owing to rapid commercialization after advancements in mRNA platform technologies, increasing mRNA applications beyond vaccines, and increasing investments in oncology, rare diseases and personalized medicine.
• RNA Interference (RNAi) is estimated to register the highest CAGR of 15.1% during the forecast period, due to increasing regulatory approvals, increasing clinical pipelines, improved gene silencing technologies, and growing adoption for the treatment of rare genetic and metabolic disorders.
• The Infectious Diseases indication segment is the leading segment with an estimated share of 37.9% in 2025, driven by sustained investment in antiviral therapies, vaccine development and rapid-response RNA platforms targeting emerging infectious diseases.
• The oncology segment is expected to witness the highest CAGR of 15.6% between 2026-2036, due to the increasing development of personalized cancer therapies, tumor-targeted RNA medicines, cancer immunotherapies, and combination treatment strategies.
• Biopharmaceutical & Biotechnology Companies is the major end-user segment, projected to hold a 44.2% share in 2025, due to substantial investments in RNA drug discovery, clinical development, manufacturing scale-up, and commercialization of next-generation RNA therapeutics.
• The Contract Research and Manufacturing Organizations (CRMOs) segment is anticipated to witness the highest CAGR of 15.4% during the forecast period, driven by the growing outsourcing of RNA manufacturing, analytical testing, process development, and clinical production as pharmaceutical companies expand their RNA therapeutic pipelines.

Research Scope & Methodology

This study provides a comprehensive strategic assessment of the Global RNA Therapeutics Market across the forecast period of 2026-2036. The report examines market size, revenue projections, competitive landscape, technology trends, regulatory changes, clinical pipeline developments and emerging investment opportunities influencing the global RNA therapeutics market. The assessment covers the full value chain from RNA drug discovery, oligonucleotide synthesis, delivery technologies, manufacturing, clinical development, regulatory approval, commercialization and end-user adoption - hospitals, research institutions, biopharmaceutical companies, biotechnology companies and contract research and manufacturing organizations. The study segments the market based on Type (mRNA-based Therapeutics, RNA Interference, Antisense Oligonucleotides, Others), Indication (Infectious Diseases, Oncology, Cardiovascular Disorders, Neurological Disorders, Others) and End User (Hospitals & Clinics, Research & Academic Institutes, Biopharmaceutical & Biotechnology Companies, Contract Research and Manufacturing Organizations). Regional analysis covers North America, Europe, Asia Pacific and LAMEA and evaluates the biotechnology investments, genomic research capabilities, regulatory frameworks, clinical trial activity, manufacturing infrastructure and healthcare innovation impacting regional market growth. The report also discusses the advancements in lipid nanoparticle (LNP) delivery systems, gene silencing technologies, AI-assisted drug discovery, personalized RNA medicine, next generation oligonucleotide chemistry, gene editing platforms and scalable RNA manufacturing technologies, which continue to change the competitive landscape of the RNA therapeutics market.

The research methodology used is a combination of extensive primary and secondary research which provides reliable market data and robust long term forecasting. Primary research consists of structured interviews with pharmaceutical executives, biotechnology companies, RNA therapeutics developers, academic researchers, clinicians, contract development and manufacturing organizations (CDMOs), regulatory experts and industry consultants across the major global markets. The secondary research includes publications by international healthcare organizations, government agencies, annual reports, investor presentations, scientific journals, clinical trial registries, regulatory databases, biotechnology associations and verified market intelligence sources. Market estimates are derived using a combination of top-down and bottom-up approaches and validated through data triangulation across all market segments and regional level analyses. Forecast models incorporate historic approvals of RNA therapeutics, progress in the clinical pipeline, pharmaceutical R&D expenditure, prevalence of chronic and genetic diseases, biotech funding and technological innovation. Competitive benchmarking offers an in-depth analysis of product portfolios, clinical pipelines, manufacturing capabilities, R&D investments, strategic collaborations, geographic presence, regulatory approvals and commercialization strategies of the leading market participants to understand the current competitive landscape and the future position of market players in the Global RNA Therapeutics Market.

Key Market Segments

By Type:

mRNA-based Therapeutics

RNA Interference

Antisense Oligonucleotides

Others

By Indication:

Infectious Diseases

Oncology

Cardiovascular Disorders

Neurological Disorders

Others

By End User:

Hospitals & Clinics

Research & Academic Institutes

Biopharmaceutical & Biotechnology Companies

Contract Research and Manufacturing Organizations

Key Market Players

Alnylam Pharmaceuticals

Sarepta Therapeutics

Novo Nordisk (RNA Unit)

Silence Therapeutics

Ionis Pharmaceuticals

Translate Bio (Sanofi)

Arbutus BioPharma

Ultragenyx Pharma

Arrowhead Pharmaceuticals

Avidity Biosciences

Omega Therapeutics

Industry Trends

• Messenger RNA (mRNA) therapeutics are rapidly expanding into oncology, rare genetic disorders, autoimmune diseases, cardiovascular diseases, and protein replacement therapies, in addition to infectious disease vaccines. Pharma companies are investing heavily in multi-pronged mRNA pipelines to broaden therapeutic opportunities and accelerate the path to commercialization.
• Lipid nanoparticle (LNP) delivery systems are still evolving and improving stability, targeted delivery and intracellular uptake of RNA therapeutics. Improved delivery technologies are facilitating more efficient, tissue specific targeting with decreased off-target effects and improved therapeutic efficacy.
• RNA interference (RNAi) therapies are building considerable clinical momentum as regulatory approvals rise and applications broaden across rare genetic, metabolic, hepatic and cardiovascular diseases. Advances in gene silencing efficiency and targeted delivery technologies are improving the long-term commercial potential of RNAi therapeutics.
• Antisense oligonucleotide (ASO) technologies are being improved in terms of nucleotide chemistry, stability and gene selectivity. Such innovations are widening the therapeutic possibilities for neurological diseases, inherited diseases and previously untreatable genetic conditions.
• The RNA therapeutic discovery process, including target identification, RNA sequence optimization, molecular modeling, toxicity prediction and clinical candidate selection, is being increasingly guided by artificial intelligence (AI). The RNA therapeutics pipeline sees reduced development timelines and improved research productivity thanks to AI-driven drug development.
• Personalized RNA medicine is becoming a major focus of the industry, as the ability to create customized therapies based on an individual's genetic makeup and disease-specific mutations becomes possible. Investment in precision RNA therapeutics is increasing for use in oncology, rare diseases and personalized immunotherapy.
• As the global demand for RNA therapeutics increases, manufacturing technologies are becoming increasingly scalable and automated. Companies are investing in advanced synthesis platforms, continuous manufacturing processes and high-throughput quality control systems to increase production efficiency and commercial scalability.
• Innovations in the RNA therapeutics ecosystem are being driven through collaborations between pharmaceutical companies, biotech companies, academic institutions and contract development and manufacturing organizations (CDMOs). Licensing, co-development and manufacturing partnerships are increasing research capabilities around the world and speeding up clinical development.
• Regulatory agencies are also working to establish clearer development pathways and expedited approval mechanisms for innovative RNA-based therapies. As regulatory experience with mRNA vaccines and gene-silencing therapies grows, we are seeing more widespread clinical development of these programs in multiple therapeutic indications.
• The use of RNA therapeutics in combination treatment strategies is growing increasingly common. RNA medicines are being combined with immunotherapies, targeted therapies, gene editing technologies and traditional pharmaceuticals to improve therapeutic efficacy, overcome treatment resistance and expand applications for complex diseases.
  • Market Determinants
• Growing Prevalence of Chronic, Rare, and Genetic Diseases: The increasing global burden of cancer, cardiovascular diseases, neurological disorders, infectious diseases, and rare genetic conditions is a major driver of the RNA therapeutics market. RNA-based medicines offer highly targeted mechanisms of action capable of addressing diseases that are difficult to treat using conventional small molecules or biologics, thereby expanding their clinical adoption.
• Advancements in RNA Delivery Technologies and Molecular Engineering: Continuous innovation in lipid nanoparticle (LNP) delivery systems, conjugate technologies, oligonucleotide chemistry, and targeted delivery platforms has significantly improved the stability, efficacy, and safety of RNA therapeutics. These technological advancements are accelerating clinical development and expanding the range of treatable diseases.
• Increasing Investments in Precision Medicine and Biotechnology Research: Governments, pharmaceutical companies, and biotechnology firms are significantly increasing investments in genomic medicine, gene-based therapies, and precision healthcare. Growing research funding, expanding RNA therapeutic pipelines, and rising strategic collaborations between academia and industry continue to strengthen market growth.
• Favorable Regulatory Support and Expanding Clinical Pipelines: Regulatory agencies are increasingly supporting the development of innovative RNA-based medicines through accelerated review pathways, orphan drug incentives, and breakthrough therapy designations. Simultaneously, the growing number of clinical trials involving mRNA therapeutics, RNA interference (RNAi), and antisense oligonucleotides is driving long-term commercialization opportunities.
• High Development Costs and Manufacturing Complexity: RNA therapeutics require sophisticated research platforms, advanced manufacturing technologies, stringent quality control systems, and specialized delivery mechanisms. High development costs, expensive clinical trials, and complex large-scale manufacturing processes may limit market entry for smaller biotechnology companies and delay commercialization.
• Delivery Challenges and Regulatory Compliance Requirements: Despite significant progress, achieving efficient tissue-specific delivery while minimizing immune responses and off-target effects remains a technical challenge for several RNA therapeutic platforms. In addition, manufacturers must comply with rigorous regulatory requirements governing safety, efficacy, manufacturing consistency, and long-term clinical monitoring, which can increase development timelines and operational costs.

Opportunity Mapping Based on Market Trends

• Expansion of Personalized and Precision RNA Medicines: Rapid advances in genomics, molecular diagnostics, and biomarker identification are creating substantial opportunities for personalized RNA therapeutics. Increasing demand for patient-specific treatments targeting rare genetic mutations, individualized cancer therapies, and precision medicine approaches is expected to accelerate the development and commercialization of next-generation RNA-based drugs.
• Growing Applications Beyond Infectious Diseases: The success of mRNA technology has significantly broadened research into oncology, cardiovascular diseases, autoimmune disorders, neurological diseases, metabolic disorders, and regenerative medicine. Expansion into these high-burden therapeutic areas presents significant long-term growth opportunities for pharmaceutical and biotechnology companies developing RNA-based treatment platforms.
• Advancements in RNA Delivery Technologies and Manufacturing: Continuous innovation in lipid nanoparticle (LNP) delivery systems, ligand-targeted delivery, novel oligonucleotide chemistries, and scalable manufacturing technologies is creating opportunities to improve therapeutic efficacy, expand tissue-specific targeting, and reduce production costs. These advancements are expected to facilitate broader clinical adoption and commercial scalability of RNA therapeutics.
• Increasing Biotechnology Investments Across Emerging Markets: Expanding biotechnology ecosystems, rising pharmaceutical research investments, strengthening clinical trial infrastructure, and growing government support for genomics and advanced therapeutics across Asia Pacific, Latin America, the Middle East, and Africa are creating favorable conditions for long-term market expansion. Increasing collaboration between global pharmaceutical companies and regional biotechnology firms is expected to further accelerate adoption of RNA therapeutics in these emerging markets.

Value-Creating Segments and Growth Pockets

mRNA Platform Commercialization and Delivery Advances Sustain RNA Therapeutics Market Leadership

mRNA-based Therapeutics are projected to account for the largest market position, reaching approximately USD 7.2 billion in 2025 with a CAGR of 31.9%, supported by successful commercialization of mRNA platforms, expanding therapeutic applications beyond vaccines, increasing investment in oncology and rare disease research, and continued advances in lipid nanoparticle (LNP) delivery technologies. The growing clinical validation of mRNA platforms is enabling their application across a broader range of therapeutic areas, while improvements in stability, delivery efficiency, and manufacturing scalability are expanding commercialization potential. Continued investment in next-generation mRNA technologies and development of personalized therapeutics is expected to sustain the segment's strong market position.

RNA Interference (RNAi) is projected to register the highest CAGR of 15.1% during 2026-2036, driven by increasing regulatory approvals, expanding clinical pipelines, improved gene-silencing efficiency, and growing adoption for rare genetic, metabolic, hepatic, and cardiovascular disorders. Advances in targeted delivery systems are improving the ability of RNAi therapeutics to selectively reach relevant tissues and maintain effective gene silencing. Growing clinical validation and expansion into previously difficult-to-treat diseases are further strengthening the technology's commercial potential. Continued innovation in delivery platforms and RNA modification technologies is expected to accelerate segment growth.

Broad mRNA Applications and Antiviral Innovation Sustain Infectious Disease Leadership

Infectious Diseases are projected to account for the largest market share of approximately 37.9% in 2025, supported by widespread adoption of mRNA-based technologies, sustained investment in antiviral therapeutics, vaccine innovation, and development of rapid-response platforms for emerging infectious diseases. RNA platforms provide the potential for rapid development and manufacturing of vaccines and therapeutics in response to evolving pathogens, supporting continued investment by pharmaceutical and biotechnology companies. Expanding research into next-generation vaccines and RNA-based antiviral treatments is further broadening the addressable market. Continued development of flexible RNA platforms and preparedness for emerging infectious diseases is expected to sustain the segment's market leadership.

Oncology is projected to register the highest CAGR of 15.6% during 2026-2036, driven by increasing development of personalized cancer therapies, tumor-targeted RNA medicines, therapeutic cancer vaccines, RNA-based immunotherapies, and combination treatment strategies. RNA technologies offer opportunities to modulate gene expression, stimulate targeted immune responses, and address molecular targets associated with individual tumor profiles. Growing investment in precision oncology and increasing clinical research into RNA-based approaches are expanding the therapeutic pipeline. Continued advances in targeted delivery, biomarker-driven treatment selection, and combination therapies are expected to accelerate adoption of RNA therapeutics in oncology.

Biopharmaceutical Investment and Commercialization Sustain Industry Market Leadership

Biopharmaceutical & Biotechnology Companies are projected to account for the largest market share of approximately 44.2% in 2025, supported by substantial investments in RNA drug discovery, clinical development, large-scale manufacturing, strategic partnerships, and commercialization of next-generation RNA therapeutics. These companies are expanding RNA pipelines across infectious diseases, oncology, rare diseases, and metabolic disorders while investing in specialized manufacturing capabilities and delivery technologies. Increasing collaboration between biotechnology companies, pharmaceutical manufacturers, technology developers, and academic institutions is further accelerating translation of RNA research into clinical and commercial products. Continued pipeline expansion and investment in RNA manufacturing infrastructure are expected to reinforce the segment's market leadership.

Contract Research and Manufacturing Organizations (CRMOs) are projected to register the highest CAGR of 15.4% during 2026-2036, driven by increasing outsourcing of RNA synthesis, process development, analytical testing, clinical manufacturing, and commercial-scale production. As pharmaceutical and biotechnology companies expand RNA therapeutic pipelines, many are seeking specialized external capabilities to manage complex manufacturing requirements while controlling development costs and accelerating timelines. CRMOs can provide access to specialized infrastructure, technical expertise, scalable production capabilities, and regulatory support across different stages of the product lifecycle. Continued growth of RNA pipelines and increasing demand for flexible, cost-efficient manufacturing models are expected to accelerate CRMOs' role in the RNA therapeutics ecosystem.

Regional Market Assessment

Biotechnology Scale and Precision Medicine Adoption Sustain North America's RNA Therapeutics Leadership

North America is projected to dominate the global RNA therapeutics market, accounting for approximately 43.6% share in 2025, supported by a mature biotechnology ecosystem, substantial pharmaceutical R&D investment, favorable regulatory pathways, and advanced genomic medicine infrastructure. The United States represents the leading regional market, benefiting from the presence of major RNA therapeutics developers, extensive clinical trial activity, sophisticated manufacturing capabilities, and growing adoption of precision medicine. Continued investment in mRNA technologies, RNA interference platforms, and next-generation oligonucleotide therapies is expanding the therapeutic pipeline and strengthening commercialization capabilities. Further advances in RNA delivery, manufacturing, and clinical development are expected to sustain North America's market leadership.

Biotech Research and Collaborative Development Strengthen Europe's RNA Therapeutics Market

Europe represents a significant market for RNA therapeutics, supported by strong biotechnology research capabilities, increasing government support for life sciences, and expanding clinical development programs. Countries including Germany, the United Kingdom, France, Switzerland, and Belgium continue to invest in genomic medicine, advanced biologics manufacturing, and innovative RNA-based therapies. Collaboration between academic institutions, biotechnology companies, and pharmaceutical organizations is accelerating translational research and supporting the development of new RNA therapeutic platforms. Growing investment in precision medicine and advanced manufacturing capabilities is further strengthening the regional ecosystem. Continued research collaboration and supportive life sciences policies are expected to drive sustained market expansion.

Biotechnology Expansion and Genomics Investment Accelerate Asia Pacific Growth

Asia Pacific is projected to register the highest CAGR of 15.2% during the forecast period, driven by expanding biotechnology industries, increasing pharmaceutical investment, government support for genomics research, and growing clinical trial activity across China, Japan, South Korea, India, and Singapore. Regional governments and pharmaceutical companies are increasingly investing in biotechnology infrastructure, advanced manufacturing capabilities, and precision medicine programs. Regulatory reforms and growing clinical research capacity are also improving the region's attractiveness for RNA therapeutic development and commercialization. Continued investment in genomics, biopharmaceutical manufacturing, and RNA research is expected to make Asia Pacific the fastest-growing regional market.

Healthcare Modernization and Biotechnology Partnerships Create LAMEA Opportunities

LAMEA is emerging as a promising market for RNA therapeutics, supported by improving healthcare infrastructure, expanding biotechnology capabilities, increasing clinical research activity, and growing investment in advanced therapies. Countries including Brazil, Saudi Arabia, the United Arab Emirates, South Africa, and Mexico are strengthening pharmaceutical research capabilities, genomics programs, and biotechnology partnerships. Increasing collaboration with global pharmaceutical and biotechnology organizations is also helping develop local expertise and research infrastructure. Continued investment in precision medicine, advanced therapeutics, and biotechnology ecosystems is expected to create long-term opportunities for RNA therapeutics across the region.

Recent Developments

• May 2025: Alnylam Pharmaceuticals expanded its RNA interference (RNAi) pipeline through continued advancement of next-generation gene-silencing therapies targeting rare genetic and cardiometabolic diseases.
• March 2025: Ionis Pharmaceuticals announced progress in its antisense oligonucleotide development programs, expanding its clinical portfolio across neurological and rare genetic disorders through strategic research collaborations.
• October 2024: Arrowhead Pharmaceuticals advanced multiple RNAi therapeutic candidates utilizing proprietary targeted RNA delivery platforms to address liver, pulmonary, and cardiovascular diseases.
• July 2024: Sanofi, through its Translate Bio platform, continued investments in mRNA research and manufacturing capabilities to accelerate the development of innovative RNA-based therapeutics beyond infectious disease applications.

Critical Business Questions Addressed

How will the Global RNA Therapeutics Market evolve through 2036?

The report evaluates long-term market growth driven by expanding RNA technology platforms, increasing precision medicine adoption, advances in RNA delivery systems, and growing commercialization of gene-based therapeutics.

Which type, indication, and end-user segments will generate the greatest commercial opportunities?

The study identifies the dominant and fastest-growing market segments, enabling pharmaceutical companies, biotechnology firms, investors, and healthcare organizations to prioritize strategic investments.

What are the primary factors driving market expansion?

The report analyzes the influence of chronic disease prevalence, genomic medicine, RNA platform innovation, regulatory support, biotechnology funding, and advancements in targeted drug delivery on future market development.

Which regional markets present the strongest long-term investment potential?

The assessment compares biotechnology ecosystems, pharmaceutical R&D investments, clinical trial activity, manufacturing capabilities, regulatory environments, and healthcare innovation across major regions to identify the most attractive growth opportunities.

How can RNA therapeutics developers strengthen their competitive position in the evolving industry?

The report examines strategic priorities including next-generation RNA delivery technologies, artificial intelligence-assisted drug discovery, manufacturing scale-up, strategic collaborations, pipeline diversification, and personalized medicine initiatives to support long-term competitive advantage.

Beyond the Forecast

• The RNA therapeutics market will increasingly benefit from advances in lipid nanoparticle delivery systems, targeted RNA engineering, artificial intelligence-driven drug discovery, gene editing technologies, and scalable manufacturing platforms, enabling safer, more effective, and highly personalized therapies.
• Rising investments in precision medicine, rare disease treatment, oncology, cardiovascular therapeutics, and next-generation vaccine technologies will continue creating substantial opportunities for pharmaceutical companies, biotechnology firms, and contract manufacturing organizations across developed and emerging markets.
• As healthcare systems prioritize targeted therapies, genomic medicine, and personalized treatment approaches, companies investing in innovative RNA platforms, advanced delivery technologies, clinical pipeline expansion, and global manufacturing capabilities will be well positioned to capitalize on long-term growth opportunities in the global RNA therapeutics market through 2036.